What does Jasper Therapeutics do?

Jasper Therapeutics is a clinical-stage biotechnology company based in Menlo Park, California. The company is dedicated to developing safer conditioning agents and therapeutics, particularly monoclonal antibodies that target c-Kit (CD117). Their goal is to enhance the use of curative hematopoietic stem cell transplants, gene therapies, and treatments for chronic immunological diseases, including chronic urticaria and asthma. The company's lead product, briquilimab, is in clinical development for chronic spontaneous urticaria and chronic inducible urticaria, with planned studies in asthma patients. Jasper Therapeutics also previously developed JSP191, an antibody designed to facilitate stem cell transplants. The company emphasizes collaboration with academic institutions and aims to make effective therapies more accessible to patients in need.